Genotyping Of Warfarin Patients Will Be Discussed By FDA's Clinical Pharmacology Subcommittee
This article was originally published in The Pink Sheet Daily
Executive Summary
The subcommittee will consider whether warfarin labeling should be changed to recommend lower starting doses for patients with certain genotypes at Nov. 14-15 meeting.